Message-ID: <199712212357.NAA06174@spartacus.hula.net> Date: Sun, 21 Dec 1997 13:57:32 -1000 From: "Pacific Synergy Inc. (PSI)" <mailto:synergy@HULA.NET> Subject: CENTRIFUGAL BIOREACTOR: Licensing and technology transfer To: mailto:DEVEL-L@AMERICAN.EDU
Dear People and Organizations of the List,Attached is a descritption of the Centrifugal Bioreactor (CBR). We are offering exclusive, on a per-country basis, or world wide rights, to market, to sell, to install, to maintain, and to upgrade its proprietary, patented products in either specific application areas or for all possible applications areas, including but not limited to, those enumerated below. This will involve an up-front fee and a royalty schedule in either circumstance. From a competitive viewpoint, such an arrangement will grant an enormous advantage to a CBR licensee, in that for the national market of interest, no other entity will be so licensed to market these revolutionary CBR systems in the designated country.
This technology has revolutionary implications. Please read through. Please refer to potentially interested candidates.
Peter R. Ziegler, C.E.O. Pacific Synergy Inc and The Sustainable Development Institute (808) 531-6127 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|||||||||
KINETIC BIOSYSTEMS, INC. The Centrifugal Bio Reactor (CBR): A Revolutionary Bio-Production Technology.BACKGROUND: The world's smallest creatures generate one of the world's largest markets. Microorganisms and animal cells produce a current-year projected $350 Billion/year worldwide in fermentation and other bio-products, ranging across antibiotics, vaccines, fuel alcohol, commodity chemicals, waste treatment processes, and toxic/hazardous/radioactive site remediation. Already, thousands of new bio-processed drugs are being developed for human use, promising an additional, ever-increasing future opportunity for this critical kind of bio-production.
Current bio-production machines, called bioreactors, are typically vat-like and operate in an intermittent "batch mode" that is inefficient and labor-intensive, requiring complex equipment, expensive highly-trained personnel and costly capital outlays.
We have developed, patented, prototyped, and successfully commercially tested a new bioreactor technology. Called the Centrifugal Bio Reactor (CBR), it produces all types of microbes and cells IN CONCENTRATIONS FROM 1,000 to 100,000 TIMES MORE DENSE THAN ANY COMPETING PROCESS, with dramatically increased per-cell productivity.
With these unique and patented proprietary features, our CBR systems will rapidly produce and utilize industrial-capacity bioproducts IN SPACE HUNDREDS OF TIMES SMALLER THAN ANY COMPETING PROCESS WITH MUCH SIMPLER EQUIPMENT, AND AT A MUCH LOWER COST. FOR EXAMPLE, THE EQUIVILANT OF A PRESENT-DAY 10,000 LITER FERMENTATION FACILITY, THE SIZE OF A MULTI-STORY COMMERCIAL BUILDING, CAN BE REPLACED BY A CBR MACHINE SYSTEM THAT WILL FIT IN THE AVERAGE ROOM OF A HOUSE. Or, a CBR-based waste treatment facility could be installed IN LESS THAN ONE-HUNDREDTH of the area required for conventional facilities. Thus CBR technology stands to replace conventional bio-reators in nearly all bio-production and bio-remediation systems.
Specifically, what follows is an overview of exactly what areas our CBR technology will cover all areas of the world. Our CBR technology will be able to greatly aid the following strategic markets (areas):
(a) The waste and sewage industry.
(b) All types of water treatment.
(c) The industrial waste treatment industry.
(d) The pulp and paper industry, and the production of cellulose for that industry.
(e) Toxic and radioactive site remediation for both Government and industry.
(f) Transportable waste processing for the military, commercial ships plus other mobile installations.
(g) Health care products and drugs made by fermentation, i.e. vaccines, steroids, hormones, monoclonal antibodies, and anti-cancer agents such as Interferon, TNF and Interleukins. ALSO, insulin and human growth hormones are made from human-derived cells using batch fermentation.
(h) The consumer alcohol market such as beer, wine and liquor which uses fermentation.
(i) The major commodity fermentation industry which include Ethanol production (fuel alcohol from plants) plus food additives such as Aspartame, penicillin, monosodium glutanate, citric acid and other additives, chemicals and enzymes.
(j) Many, many other applications and more coming on stream all the time.
Please note that the owner of an exclusive representation will control that specific area of the world for all time and further benefit as more technologies are discovered and made available under the exclusive license agreement.
EXAMPLE: The licensee will be the exclusive provider of CBR technology for all of the above, but will also become the provider of choice for laboratory scale systems used in the research labs by government, industry, and academia. Also, the sole supplier of CBR based bioreactor equipment that is at the heart of extremely small and efficient sewage and waste treatment systems including those capable of being utilized for apartment complexes, hotels and small communities. Plus the supplier of choice for all other applications of our CBR systems as we achieve world-wide recognition for the efficacy of our products.
Our CBR technology will be the standard of production for the biotechnology industry, regardless of what biomolecules the industry uses. We will maintain this leadership in technology, and our markets will continue to increase along with the biotechnology industry. These factors give our licensees a very strong position as supplier of CBR products to all segments of the worldwide biotechnology industry.
NOTE: Please keep in mind that our CBR technology already exists. Our initial two clients were Georgia State University, for hybridoma cell research and Sago Technologies Inc., a private company for applications involving the production of CMA (a road salt substitute) and for research into angiotensin, a protein peptide being studied as a cancer treatment.
Peter R. Ziegler mailto:synergy@hula.net